Marco Dotti, MD
Neurology · Stevens Point, WINPI 1508916263
Payments from drug & device makers
Across 153 payments — averaging $57.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$955
- Inspire Medical Systems, Inc.$861
- Novartis$728
- Biogen$633
- Pfizer$414
- plus $4K from 24 others
What the payments were for
- Food & beverage$8,25893%
- Education$5817%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| EMD Serono, Inc. | 14 | $1,155 |
| Teva Pharmaceuticals USA, Inc. | 13 | $955 |
| Inspire Medical Systems, Inc. | 16 | $861 |
| Novartis | 17 | $728 |
| Biogen | 9 | $633 |
| Pfizer | 7 | $414 |
| TG Therapeutics, Inc. | 4 | $385 |
| Harmony Biosciences LLC | 10 | $377 |
| AbbVie(2 entities) | 8 | $344 |
| E.r. Squibb & Sons, L.L.C. | 3 | $294 |
| Lilly USA, LLC | 12 | $289 |
| Neurelis, Inc. | 3 | $271 |
| AstraZeneca | 4 | $261 |
| MDD US Operations, LLC | 4 | $248 |
| UCB, Inc. | 2 | $245 |
| Eisai Inc. | 5 | $242 |
| Bristol Myers Squibb | 4 | $208 |
| Jazz Pharmaceuticals Inc. | 5 | $160 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $125 |
| SK Life Science, Inc. | 1 | $125 |
| Corium, LLC | 2 | $106 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $106 |
| Johnson & Johnson | 1 | $98 |
| Amgen | 1 | $63 |
| Biohaven Pharmaceuticals, Inc. | 1 | $58 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $19 |
| Argenx US, Inc. | 1 | $18 |
| Sandoz | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
| Neurocrine Biosciences, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,840 in reported general payments places this provider in the 75th percentile of 308 neurology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 41 | $439,054 |
| AustedoDeutetrabenazine | 47 | $362,095 |
| HetliozTasimelteon | 11 | $246,185 |
| NuplazidPimavanserin Tartrate | 12 | $64,574 |
| GocovriAmantadine Hcl | 11 | $37,780 |
| ZonegranZonisamide | 15 | $34,097 |
| FycompaPerampanel | 12 | $17,051 |
| DepakoteDivalproex Sodium | 20 | $12,045 |
| Lamotrigine ErLamotrigine | 34 | $11,688 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 393 | $10,187 |
| NeuproRotigotine | 12 | $10,129 |
| SunosiSolriamfetol Hcl | 11 | $9,441 |
| RytaryCarbidopa/Levodopa | 20 | $9,352 |
| Levetiracetam | 270 | $7,808 |
| Rasagiline Mesylate | 57 | $5,809 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $955 | $801,14988 claims |
| MDD US Operations, LLCGocovri | $248 | $37,78011 claims |
| Eisai Inc.Fycompa, Dayvigo | $242 | $21,03024 claims |
| UCB, Inc.Neupro | $245 | $10,12912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 308 neurology providers in Wisconsin.
Other neurology in Stevens Point
- Bhupendra KhatriMilwaukee$7.3M
- Ahmed ObeidatMilwaukee$6M
- James NapierGreen Bay$1.7M
- Malgorzata FranczakMilwaukee$1.7M
- Staley BrodMilwaukee$1.3M
- Daniel LongNeenah$1.2M
- Ankush BhatiaMadison$983K
- Sam HooshmandMilwaukee$783K
- Aaron BubolzGreen Bay$595K
- Christopher LuzzioMadison$555K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.